CTOs on the Move


 
Afaxys mission is to deliver products and services to public health providers affordably, reliably and with an unwavering focus on customer service.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.afaxys.com
  • 455 1/2, King St
    Charleston, SC USA 29403
  • Phone: 855.888.2467

Executives

Name Title Contact Details

Similar Companies

Pharmaceutics International

Pharmaceutics International, Inc. (Pii) is a US-based contract development and manufacturing organization (CDMO) with a passion for solving problems. Pii`s Hunt Valley, Maryland, campus includes 70 manufacturing suites with four integrated aseptic filling lines. We offer contract analytical development and support formulation and manufacturing of oral solid dosage forms. Our professionals have extensive experience with small and large molecule compounds, developing and manufacturing complex parenteral drugs, extended-release formulations, non-aqueous injectable drug products, lyophilization, and DEA scheduled drugs.

Institute for OneWorld Health

Institute for OneWorld Health is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ABcann Global

Our group of companies will be the first to produce repeatable, standardized, plant-based medicines worldwide. ABcann will produce products with integrity in a customer focused culture where social responsibility and environmental impacts are mandated.

MANCEF

MANCEF is a Albuquerque, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.